In terms of safety, drug‐related adverse events such as UTI and hypoglycemia found during the trial were similar to those recorded in previous SGLT2 trials, and no new drug‐specific adverse events were identified. This evidence concerns the gene SLC5A2 and bacterial urinary tract infection.